Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
UCLA Unveils Innovative Therapy to Combat Pancreatic Cancer
Researchers at UCLA have announced a significant advancement in cancer treatment with the development of an off-the-shelf cell-based immunotherapy aimed at combating pancreatic cancer. This pioneering therapy has demonstrated the ability to locate and destroy pancreatic cancer cells, even those that have metastasized to other organs.
During a recent study conducted on mice, the treatment not only slowed the progression of cancer but also extended survival rates. Remarkably, it maintained its effectiveness in the challenging environment of solid tumors.
Lead author Dr. Yanruide Li, a postdoctoral scholar at UCLA, emphasized the therapy’s multifaceted approach. Even when pancreatic cancer attempts to evade treatment by altering its molecular profile, the therapy launches attacks from several angles simultaneously, overwhelming the tumor’s ability to adapt.
The Mechanism Behind the Immunotherapy
To create this innovative therapy, researchers transformed human stem cells into a specialized type of immune cell known as invariant natural killer T cells, or NKT cells. Subsequently, they genetically engineered these cells by incorporating a chimeric antigen receptor (CAR). This modification allows the NKT cells to identify and target pancreatic cancer cells effectively.
A significant advantage of NKT cells lies in their universal compatibility with different immune systems. This compatibility facilitates their entry into the body without triggering adverse reactions. The researchers further noted that these cells can be mass-produced from donated blood stem cells.
One donor could yield enough cells for thousands of treatments, suggesting a pathway toward cost-effective and accessible cancer therapies.
Testing the Therapy in Laboratory Models
The research team conducted extensive testing of the therapy in various laboratory models. These included scenarios where cancer cells were directly introduced into the pancreas and models that simulated the disease’s spread to critical organs such as the liver and lungs.
In their findings, the researchers discovered that CAR-NKT cells demonstrated a remarkable ability to infiltrate the tumor, unlike many immune treatments that often struggle to penetrate solid masses. Once inside, these engineered cells employed various detection methods to locate cancer cells, utilizing multiple mechanisms to eradicate them.
The durability of these engineered immune cells represents a crucial advancement. Many immune cells tend to become overwhelmed and inactive when faced with solid tumors. In contrast, these CAR-NKT cells remained active, capable of continuously combating the cancer over an extended period.
Research Findings Published in Top Journals
The results of this groundbreaking research were published in the journal Proceedings of the National Academy of Sciences (PNAS). Senior author Dr. Lili Yang, a professor specializing in microbiology, immunology, and molecular genetics at UCLA, expressed optimism about the therapy’s potential. She highlighted the significance of developing a treatment that can efficiently target both primary tumors and their metastases, thereby changing the landscape of pancreatic cancer treatment.
The preliminary research indicates that a single treatment could cost approximately $5,000, which is considerably lower than more personalized CAR-T therapies. This cost-effectiveness could address affordability barriers and improve accessibility for patients diagnosed with pancreatic cancer.
Addressing the Challenges of Pancreatic Cancer
Pancreatic cancer poses a formidable challenge due to its aggressive nature and the difficulties associated with treatment. Often, patients do not receive a diagnosis until the disease has already progressed extensively. The unique biology of pancreatic tumors creates physical and chemical barriers that diminish the efficacy of traditional treatments.
An additional benefit of this new therapy is its potential application beyond pancreatic cancer. Its targeting of a prevalent protein also found in breast, ovarian, and lung cancers could pave the way for treatment options that extend to other cancer types. Preliminary studies have already illustrated its effectiveness against triple-negative breast cancer and ovarian cancer.
Next Steps and Future Outlook
In light of the promising early results, the UCLA research team plans to submit applications to the Food and Drug Administration for approval to begin human trials. Dr. Yang underscored the importance of this next step, stating that proving the therapy can achieve similar outcomes in human patients, as observed in preclinical studies, is critical.
To date, all experiments have been conducted on mice. Researchers pointed out that solid tumors in humans are significantly more complex. Human tumors possess the ability to evolve and eliminate the targets that therapies are designed to address. This evolution raises concerns about the risk of cancer cells escaping detection and continuing to proliferate.
Long-term safety and potential side effects of the therapy in humans remain to be investigated before clinical trials commence. Furthermore, the researchers highlighted that the mass production of identical, safe cells presents logistical and regulatory challenges that need to be addressed.
Final Thoughts on the Breakthrough
The advancements achieved by UCLA researchers represent a beacon of hope in the ongoing battle against pancreatic cancer. By harnessing the power of engineered immune cells, they have unlocked a new avenue for treatment that not only combats the primary tumor but also addresses metastases effectively. The implications of this research could reshape cancer treatment paradigms, offering new hope for patients facing one of the most challenging cancer diagnoses.
